Spots Global Cancer Trial Database for refractory b acute lymphoblastic leukemia

Every month we try and update this database with for refractory b acute lymphoblastic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies	NCT05418088	Recurrent Acute... Recurrent B Acu... Recurrent B-Cel... Recurrent Chron... Recurrent High ... Recurrent Indol... Recurrent Non-H... Recurrent Trans... Refractory Acut... Refractory B Ac... Refractory B-Ce... Refractory Chro... Refractory High... Refractory Indo... Refractory Non-... Refractory Tran...	Anti-CD19/CD20/... Cyclophosphamid... Fludarabine Pho...	18 Years -	Ohio State University Comprehensive Cancer Center
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia	NCT02981628	Recurrent B Acu... Recurrent B Lym... Refractory B Ac... Refractory B Ly...	Asparaginase Er... Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cyclophosphamid... Cytarabine Diagnostic Imag... Inotuzumab Ozog... Leucovorin Calc... Lumbar Puncture Methotrexate Pegaspargase Vincristine	1 Year - 21 Years	Children's Oncology Group
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	NCT05032183	Recurrent Adult... Recurrent B Acu... Recurrent T Acu... Refractory B Ac... Refractory Lymp... Refractory T Ac...	Cyclophosphamid... Cytarabine Dexamethasone Filgrastim-sndz Leucovorin Mercaptopurine Mesna Methotrexate Pegfilgrastim Prednisone Rituximab Tagraxofusp-erz... Vincristine	18 Years - 70 Years	M.D. Anderson Cancer Center
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	NCT05936229	Recurrent B Acu... Recurrent B-Cel... Refractory B Ac... Refractory B-Ce... Recurrent Mantl... Refractory Mant...	Interferon Beta... X-Ray Imaging Echocardiograph... Multigated Acqu... Computed Tomogr... Positron Emissi... Lumbar Puncture Bone Marrow Asp... Bone Marrow Bio... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	NCT04681105	Recurrent Acute... Recurrent B Acu... Recurrent Blast... Recurrent Chron... Recurrent Hairy... Recurrent Hemat... Recurrent Hodgk... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Blas... Refractory Chro... Refractory Hair... Refractory Hema... Refractory Hodg... Refractory T Ac... Systemic Mastoc...	Acetaminophen Dexamethasone Diphenhydramine Flotetuzumab Ibuprofen Ranitidine	12 Years -	City of Hope Medical Center
Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia	NCT04094766	Refractory B Ac... Relapse B Acute...	Dual Specificit...	14 Years - 60 Years	Second Affiliated Hospital of Xi'an Jiaotong University
Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia	NCT04723901	Dual-target CAR... B ALL Relapse Refractory B Ac...	Dual target CAR...	14 Years - 75 Years	Shenzhen University General Hospital
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat	NCT05320380	Recurrent Acute... Recurrent B Acu... Recurrent Mixed... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Mixe... Refractory T Ac...	Anti-CD123 ADC ... Bone Marrow Asp... Cytarabine Fludarabine Pho... Hydrocortisone ... Liposome-encaps... Methotrexate Prednisolone	12 Months - 22 Years	Children's Oncology Group
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia	NCT03698552	Blasts 5 Percen... CD22 Positive Philadelphia Ch... Recurrent B Acu... Refractory B Ac...	ADCT-602	18 Years -	M.D. Anderson Cancer Center
CD19-Specific T Cells Post AlloSCT	NCT03579888	B Acute Lymphob... Recurrent B Acu... Recurrent Chron... Recurrent Diffu... Recurrent Mantl... Recurrent Non-H... Recurrent Ph-Li... Recurrent Prima... Recurrent Small... Refractory B Ac... Refractory Chro... Refractory Diff... Refractory Mant... Refractory Non-... Refractory Ph-L... Refractory Prim... Refractory Smal...	Autologous CD19... Cyclophosphamid... Fludarabine	18 Years - 70 Years	M.D. Anderson Cancer Center
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia	NCT03518112	Philadelphia Ch... Recurrent B Acu... Refractory B Ac...	Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Filgrastim Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Pegfilgrastim Rituximab Vincristine Sul...	18 Years -	M.D. Anderson Cancer Center
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat	NCT05320380	Recurrent Acute... Recurrent B Acu... Recurrent Mixed... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Mixe... Refractory T Ac...	Anti-CD123 ADC ... Bone Marrow Asp... Cytarabine Fludarabine Pho... Hydrocortisone ... Liposome-encaps... Methotrexate Prednisolone	12 Months - 22 Years	Children's Oncology Group
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	NCT05936229	Recurrent B Acu... Recurrent B-Cel... Refractory B Ac... Refractory B-Ce... Recurrent Mantl... Refractory Mant...	Interferon Beta... X-Ray Imaging Echocardiograph... Multigated Acqu... Computed Tomogr... Positron Emissi... Lumbar Puncture Bone Marrow Asp... Bone Marrow Bio... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia	NCT02420717	Recurrent B Acu... Recurrent Ph-Li... Refractory B Ac... Refractory Ph-L...	Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Laboratory Biom... Leucovorin Mercaptopurine Methotrexate Prednisone Rituximab Ruxolitinib Pho... Vincristine	10 Years -	M.D. Anderson Cancer Center
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia	NCT03518112	Philadelphia Ch... Recurrent B Acu... Refractory B Ac...	Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Filgrastim Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Pegfilgrastim Rituximab Vincristine Sul...	18 Years -	M.D. Anderson Cancer Center
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia	NCT03472573	Recurrent B Acu... Refractory B Ac...	Palbociclib Dexamethasone	18 Years -	Thomas Jefferson University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: